Hemab
Klaus Krainer Jønsson, MSc, is Finance Director of Hemab. He has more than 20 years of experience in the finance sector, and he has held finance leadership positions at Y-mAbs Therapeutics, Novo Nordisk, Roche and Nycomed, among others. He received an MSc in Business Economics and Auditing from Copenhagen Business School, Denmark.
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.